An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120

Virology

Volumn 401, Issue 2, 2010, Pages 293-304

  Moseri, Adi ^a   Tantry, Subramanyam ^b   Sagi, Yael ^a   Arshava, Boris ^b   Naider, Fred ^b   Anglister, Jacob ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Constrained peptides; Gp120; HIV 1; Neutralizing antibodies; V3 loop; Vaccine

Indexed keywords

C4 PEPTIDE VACCINE DERIVATIVE; GLYCOPROTEIN GP 120; PEPTIDE VACCINE; UNCLASSIFIED DRUG; V3 PEPTIDE VACCINE; V3 PEPTIDE VACCINE DERIVATIVE; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; SUBUNIT VACCINE;

AMINO TERMINAL SEQUENCE; ANTIBODY TITER; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CROSS REACTION; DISULFIDE BOND; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; VIRUS NEUTRALIZATION; VIRUS STRAIN; ANIMAL; BLOOD; CHEMISTRY; FEMALE; HUMAN; IMMUNOLOGY; RABBIT;

HUMAN IMMUNODEFICIENCY VIRUS 1; ORYCTOLAGUS CUNICULUS;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; CROSS REACTIONS; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; RABBITS; VACCINES, SUBUNIT;

EID: 77952299639     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.03.007     Document Type: Article

References (40)

1. Bell C.H., Pantophlet R., Schiefner A., Cavacini L.A., Stanfield R.L., Burton D.R., Wilson I.A. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. J. Mol. Biol. 2008, 375(4):969-978.
2. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 2004, 78(23):13232-13252.
3. Bryder K., Sbai H., Nielsen H.V., Corbet S., Nielsen C., Whalen R.G., Fomsgaard A. Improved immunogenicity of HIV-1 epitopes in HBsAg chimeric DNA vaccine plasmids by structural mutations of HBsAg. DNA Cell Biol. 1999, 18(3):219-225.
4. Burke B., Gomez-Roman V.R., Lian Y., Sun Y., Kan E., Ulmer J., Srivastava I.K., Barnett S.W. Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits. Virology 2009, 387(1):147-156.
5. Cabezas E., Wang M., Parren P.W., Stanfield R.L., Satterthwait A.C. A structure-based approach to a synthetic vaccine for HIV-1. Biochemistry 2000, 39(47):14377-14391.
6. Chakraborty K., Durani V., Miranda E.R., Citron M., Liang X., Schleif W., Joyce J.G., Varadarajan R. Design of immunogens that present the crown of the HIV-1V3 loop in a conformation competent to generate 447-52D-like antibodies. Biochem. J. 2006, 399(3):483-491.
7. Chandrasekhar K., Profy A.T., Dyson H.J. Solution conformational preferences of immunogenic peptides derived from the principal neutralizing determinant of the HIV-1 envelope glycoprotein gp120. Biochemistry 1991, 30(38):9187-9194.
8. Conley A.J., Conard P., Bondy S., Dolan C.A., Hannah J., Leanza W.J., Marburg S., Rivetna M., Rusiecki V.K., Sugg E.E., et al. Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens. Vaccine 1994, 12(5):445-451.
9. Davis K.L., Bibollet-Ruche F., Li H., Decker J.M., Kutsch O., Morris L., Salomon A., Pinter A., Hoxie J.A., Hahn B.H., Kwong P.D., Shaw G.M. Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1V3-specific antibodies in human plasma. J. Virol. 2009, 83(3):1240-1259.
10. Davis K.L., Gray E.S., Moore P.L., Decker J.M., Salomon A., Montefiori D.C., Graham B.S., Keefer M.C., Pinter A., Morris L., Hahn B.H., Shaw G.M. High titer HIV-1V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology 2009, 387(2):414-426.
11. Dhillon A.K., Stanfield R.L., Gorny M.K., Williams C., Zolla-Pazner S., Wilson I.A. Structure determination of an anti-HIV-1 Fab 447-52D-peptide complex from an epitaxially twinned data set. Acta. Crystallogr. D. Biol. Crystallogr. 2008, D64(Pt 7):792-802.
12. Eda Y., Takizawa M., Murakami T., Maeda H., Kimachi K., Yonemura H., Koyanagi S., Shiosaki K., Higuchi H., Makizumi K., Nakashima T., Osatomi K., Tokiyoshi S., Matsushita S., Yamamoto N., Honda M. Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif. J. Virol. 2006, 80(11):5552-5562.
13. FitzGerald D.J., Fryling C.M., McKee M.L., Vennari J.C., Wrin T., Cromwell M.E., Daugherty A.L., Mrsny R.J. Characterization of V3 loop-Pseudomonas exotoxin chimeras. Candidate vaccines for human immunodeficiency virus-1. J. Biol. Chem. 1998, 273(16):9951-9958.
14. Fontenot J.D., Gatewood J.M., Mariappan S.V., Pau C.P., Parekh B.S., George J.R., Gupta G. Human immunodeficiency virus (HIV) antigens: structure and serology of multivalent human mucin MUC1-HIV V3 chimeric proteins. Proc. Natl. Acad. Sci. U. S. A. 1995, 92(1):315-319.
15. Haynes B.F., Ma B., Montefiori D.C., Wrin T., Petropoulos C.J., Sutherland L.L., Scearce R.M., Denton C., Xia S.M., Korber B.T., Liao H.X. Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates. Virology 2006, 345(1):44-55.
16. Huang C.C., Tang M., Zhang M.Y., Majeed S., Montabana E., Stanfield R.L., Dimitrov D.S., Korber B., Sodroski J., Wilson I.A., Wyatt R., Kwong P.D. Structure of a V3-containing HIV-1 gp120 core. Science 2005, 310(5750):1025-1028.
17. Kelker, et al. A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein. Kelker, H.C., Itri, V.R., Valentine FT PLoS One. 2010, 5(1):e8555.
18. Keller P.M., Arnold B.A., Shaw A.R., Tolman R.L., Van Middlesworth F., Bondy S., Rusiecki V.K., Koenig S., Zolla-Pazner S., Conard P., et al. Identification of HIV vaccine candidate peptides by screening random phage epitope libraries. Virology 1993, 193(2):709-716.
19. Koch M., Pancera M., Kwong P.D., Kolchinsky P., Grundner C., Wang L., Hendrickson W.A., Sodroski J., Wyatt R. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 2003, 313(2):387-400.
20. Mester B., Manor R., Mor A., Arshava B., Rosen O., Ding F.X., Naider F.R., Anglister J. HIV-1 peptide vaccine candidates: selecting constrained V3 peptides with highest affinity to antibody 447-52D. Biochemistry 2009.
21. Mor A., Segal E., Mester B., Arshava B., Rosen O., Ding F.X., Russo J., Dafni A., Schvartzman F., Scherf T., Naider F., Anglister J. Mimicking the structure of the V3 epitope bound to HIV-1 neutralizing antibodies. Biochemistry 2009, 48(15):3288-3303.
22. Pantophlet R., Wrin T., Cavacini L.A., Robinson J.E., Burton D.R. Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity. Virology 2008, 381(2):251-260.
23. Reeves P.J., Callewaert N., Contreras R., Khorana H.G. Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(21):13419-13424.
24. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., Benenson M., Gurunathan S., Tartaglia J., McNeil J.G., Francis D.P., Stablein D., Birx D.L., Chunsuttiwat S., Khamboonruang C., Thongcharoen P., Robb M.L., Michael N.L., Kunasol P., Kim J.H. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009.
25. Richman D.D., Wrin T., Little S.J., Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(7):4144-4149.
26. Robey F.A., Kelson-Harris T., Roller P.P., Robert-Guroff M. A helical epitope in the C4 domain of HIV glycoprotein 120. J. Biol. Chem. 1995, 270(41):23918-23921.
27. Rosen O., Chill J., Sharon M., Kessler N., Mester B., Zolla-Pazner S., Anglister J. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization. Biochemistry 2005, 44(19):7250-7258.
28. Rosen O., Sharon M., Quadt-Akabayov S.R., Anglister J. Molecular switch for alternative conformations of the HIV-1V3 region: implications for phenotype conversion. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(38):13950-13955.
29. Sha B.E., Onorato M., Bartlett J.A., Bosch R.J., Aga E., Nokta M., Adams E.M., Li X.D., Eldridge J., Pollard R.B. Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12. Aids 2004, 18(8):1203-1206.
30. Sharon M., Kessler N., Levy R., Zolla-Pazner S., Gorlach M., Anglister J. Alternative conformations of HIV-1V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure 2003, 11(2):225-236.
31. Stanfield R.L., Ghiara J.B., Ollmann Saphire E., Profy A.T., Wilson I.A. Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop. Virology 2003, 315(1):159-173.
32. Stanfield R.L., Gorny M.K., Williams C., Zolla-Pazner S., Wilson I.A. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure 2004, 12(2):193-204.
33. Stanfield R.L., Gorny M.K., Zolla-Pazner S., Wilson I.A. Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. J. Virol. 2006, 80(12):6093-6105.
34. Tolman R.L., Bednarek M.A., Johnson B.A., Leanza W.J., Marburg S., Underwood D.J., Emini E.A., Conley A.J. Cyclic V3-loop-related HIV-1 conjugate vaccines. Synthesis, conformation and immunological properties. Int. J. Pept. Protein Res. 1993, 41(5):455-466.
35. Tugarinov V., Zvi A., Levy R., Anglister J. A cis proline turn linking two beta-hairpin strands in the solution structure of an antibody-bound HIV-1IIIB V3 peptide. Nat. Struct. Biol. 1999, 6(4):331-335.
36. Tugarinov V., Zvi A., Levy R., Hayek Y., Matsushita S., Anglister J. NMR structure of an anti-gp120 antibody complex with a V3 peptide reveals a surface important for co-receptor binding. Structure 2000, 8(4):385-395.
37. Zinckgraf J.W., Winchell J.M., Silbart L.K. Antibody responses to a mucosally delivered HIV-1 gp120-derived C4/V3 peptide. J. Reprod. Immunol. 1999, 45(2):99-112.
38. Zolla-Pazner S., Cohen S., Pinter A., Krachmarov C., Wrin T., Wang S., Lu S. Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. Virology 2009.
39. Zolla-Pazner S., Cohen S.S., Krachmarov C., Wang S., Pinter A., Lu S. Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Virology 2008, 372(2):233-246.
40. Zvi A., Hiller R., Anglister J. Solution conformation of a peptide corresponding to the principal neutralizing determinant of HIV-1IIIB: a two-dimensional NMR study. Biochemistry 1992, 31(30):6972-6979.